Should Children Have Predictive Genetic Testing for FFI?
At a Glance
Predictive genetic testing for fatal familial insomnia is usually deferred until adulthood because FFI usually begins in adulthood, no preventive treatment must start in childhood, and waiting preserves the young person's choice. Concerning symptoms require medical evaluation, not self-testing.
In this answer
5 sections
Predictive genetic testing for fatal familial insomnia (FFI)—testing an asymptomatic, healthy person to see if they inherited the genetic mutation—is generally not recommended for children or teenagers. Major medical and genetic guidelines advise deferring predictive testing for adult-onset conditions until the young person reaches adulthood [1][2].
Because FFI typically begins in adulthood and currently has no preventative treatments that must be started in childhood, testing a healthy minor offers no immediate medical benefit [2][3]. Instead, deferring the test protects the child’s future right to make their own informed choice about whether or not they want to know their genetic risk status [4].
Understanding FFI Genetics
FFI is a rare genetic prion disease classically caused by a specific pathogenic variant (such as D178N) in the PRNP gene [5].
- Inheritance Risk: If one parent carries a confirmed familial pathogenic variant, each child has a 50% (1 in 2) chance of inheriting it [6].
- Confirming the Variant: Before offering targeted predictive testing to asymptomatic relatives, the diagnosis in an affected relative should ideally be confirmed and the exact familial variant identified [7].
What Predictive Testing Can and Cannot Tell You
- Positive Result: Indicates the person inherited the familial pathogenic variant. However, it cannot reliably forecast the exact age of onset, the specific sequence of symptoms, or the individual disease course [8][5].
- Negative Result: Reassuring only if the exact causative variant in the family is already known and the person did not inherit it.
- Variant of Uncertain Significance (VUS): Sometimes a test finds a gene change that is not well understood. A VUS is not a positive diagnosis of FFI.
Preserving Future Autonomy
One of the guiding ethical principles in pediatric genetics is the preservation of the child’s future autonomy, sometimes called the “right to an open future” [4]. Knowing one carries a mutation for a severe neurodegenerative disease is a profound piece of information. While some adults at risk for FFI find testing useful for life and reproductive planning, others actively choose not to know their status, preferring to live without a predictive result [9][10].
Testing a child before they have the developmental capacity to deeply understand the implications removes their choice in the matter [2]. Waiting until adulthood allows the individual to participate in specialized genetic counseling and decide for themselves what is best for their own life [11][12].
Weighing the Risks of Early Testing
Testing a healthy child for a future adult-onset disease carries specific psychosocial and practical considerations:
- Psychosocial Impact: Responses to genetic risk vary widely. While severe psychiatric crises from pediatric testing are uncommon, knowledge of a pathogenic variant can lead to anxiety, depression, or altered family dynamics [13]. Formal pre-test and post-test counseling is recommended to explore both the potential harms and benefits of knowing this information [7].
- Privacy and Insurance: Once a genetic test is performed, the result may be entered into the child’s medical record [14]. Depending on your jurisdiction’s specific laws, this could affect their future ability to obtain life, disability, or long-term care insurance [14][11]. Families should consult a genetic counselor for local legal information and privacy planning before testing.
Diagnostic vs. Predictive Testing
The recommendation to wait applies only to healthy, asymptomatic children. However, it is important not to self-diagnose based on common symptoms. Everyday severe insomnia, sweating, or heart-rate changes have many common, non-genetic causes.
FFI is exceptionally rare, and the average age of onset is around 47 [8][15]. While adolescent-onset has been reported in exceptionally rare case reports (as early as 17), genetic testing should follow a clinician’s assessment rather than being triggered by a symptom checklist [8][16].
If a child or teenager develops rapidly progressive and severe symptoms—such as sudden cognitive changes, marked coordination problems (gait instability), or severe involuntary nervous system changes (dysautonomia)—they should undergo a comprehensive medical evaluation for many possible causes [17][18]. If appropriate, diagnostic testing can be ordered to find the specific cause of their current illness [6].
Talking to Your Children and Seeking Support
The recommendation to delay testing does not mean delaying the conversation. Experts recommend gradual, developmentally appropriate communication about the family’s genetic risk [12]. As children mature, they can be introduced to the concept of the family history, paving the way for them to make their own testing decisions in adulthood.
It is completely normal for parents to feel immense anxiety about their child’s future and to want answers [2]. Seeking support from a genetic counselor or a mental health professional experienced in hereditary risk can help parents manage this uncertainty [7]. A counselor can help reframe the urge to test as an opportunity to focus on the optimal timing for the child’s future decision-making [2].
Common questions in this guide
Should a healthy child be tested for fatal familial insomnia?
What is a child's chance of inheriting FFI?
What would a positive FFI genetic test tell my child?
What does a variant of uncertain significance mean in FFI testing?
What are the possible downsides of testing a child for FFI?
What should parents do if a child develops symptoms that might seem like FFI?
How can a family prepare a child for a possible future FFI testing decision?
Related questions
Show more
Get notified when new evidence is published on Fatal familial insomnia.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.
References
References (18)
- 1
Human Genetics Society of Australasia Position Statement: Predictive and Presymptomatic Genetic Testing in Adults and Children.
Vears DF, Ayres S, Boyle J, et al.
Twin research and human genetics : the official journal of the International Society for Twin Studies 2020; (23(3)):184-189 doi:10.1017/thg.2020.51.
PMID: 32635964 - 2
Predictive Genetic Testing of Children for Adult-Onset Conditions: Negotiating Requests with Parents.
Fenwick A, Plantinga M, Dheensa S, Lucassen A
Journal of genetic counseling 2017; (26(2)):244-250 doi:10.1007/s10897-016-0018-y.
PMID: 27680566 - 3
Opportunistic genomic screening. Recommendations of the European Society of Human Genetics.
de Wert G, Dondorp W, Clarke A, et al.
European journal of human genetics : EJHG 2021; (29(3)):365-377 doi:10.1038/s41431-020-00758-w.
PMID: 33223530 - 4
Rethinking the "open future" argument against predictive genetic testing of children.
Garrett JR, Lantos JD, Biesecker LG, et al.
Genetics in medicine : official journal of the American College of Medical Genetics 2019; (21(10)):2190-2198 doi:10.1038/s41436-019-0483-4.
PMID: 30894702 - 5
PRNP D178N-129MM prion disease: Creutzfeldt-Jakob disease-like cortical ribboning without prominent early insomnia.
Wei W, Nan H, Chen Z, Li J
Frontiers in neuroscience 2026; (20()):1950003 doi:10.3389/fnins.2026.1950003.
PMID: 42857031 - 6
Genetic counseling for prion disease: Updates and best practices.
Goldman JS, Vallabh SM
Genetics in medicine : official journal of the American College of Medical Genetics 2022; (24(10)):1993-2003 doi:10.1016/j.gim.2022.06.003.
PMID: 35819418 - 7
A Practice Framework for Genetic Testing in Asymptomatic Relatives of Patients With Creutzfeldt-Jakob Disease: Experience and Insights From Israel.
Shir D, Bregman N, David AB, et al.
European journal of neurology 2026; (33(6)):e70649 doi:10.1111/ene.70649.
PMID: 42333775 - 8
Clinical profile of fatal familial insomnia: phenotypic variation in 129 polymorphisms and geographical regions.
Zhang J, Chu M, Tian Z, et al.
Journal of neurology, neurosurgery, and psychiatry 2022; (93(3)):291-297 doi:10.1136/jnnp-2021-327247.
PMID: 34667102 - 9
Preventive pharmacological treatment in subjects at risk for fatal familial insomnia: science and public engagement.
Forloni G, Roiter I, Artuso V, et al.
Prion 2022; (16(1)):66-77 doi:10.1080/19336896.2022.2083435.
PMID: 35737759 - 10
Ethical issues in the evaluation of adults with suspected genetic neuromuscular disorders.
Su X, Kang PB, Russell JA, Simmons Z
Muscle & nerve 2016; (54(6)):997-1006 doi:10.1002/mus.25400.
PMID: 27615030 - 11
Ethical issues in neurogenetics.
Uhlmann WR, Roberts JS
Handbook of clinical neurology 2018; (147()):23-36 doi:10.1016/B978-0-444-63233-3.00003-8.
PMID: 29325614 - 12
'We Should View Him as an Individual': The Role of the Child's Future Autonomy in Shared Decision-Making About Unsolicited Findings in Pediatric Exome Sequencing.
Dondorp W, Bolt I, Tibben A, et al.
Health care analysis : HCA : journal of health philosophy and policy 2021; (29(3)):249-261 doi:10.1007/s10728-020-00425-7.
PMID: 33389383 - 13
The psychological impact of genetic information on children: a systematic review.
Wakefield CE, Hanlon LV, Tucker KM, et al.
Genetics in medicine : official journal of the American College of Medical Genetics 2016; (18(8)):755-62 doi:10.1038/gim.2015.181.
PMID: 26741411 - 14
Ethical Considerations on Pediatric Genetic Testing Results in Electronic Health Records.
Kanungo S, Barr J, Crutchfield P, et al.
Applied clinical informatics 2020; (11(5)):755-763 doi:10.1055/s-0040-1718753.
PMID: 33176390 - 15
Fatal insomnia: the elusive prion disease.
Patel D, Ibrahim H, Rankin J, et al.
BMJ case reports 2021; (14(6)) doi:10.1136/bcr-2020-241289.
PMID: 34158325 - 16
Diagnostic accuracy of cerebrospinal fluid biomarkers in genetic prion diseases.
Schmitz M, Villar-Piqué A, Hermann P, et al.
Brain : a journal of neurology 2022; (145(2)):700-712 doi:10.1093/brain/awab350.
PMID: 35288744 - 17
A case of fatal familial insomnia: diagnostic and therapeutic approaches.
Rose DK, Liu AJ
Neurocase 2022; (28(1)):131-134 doi:10.1080/13554794.2021.2025249.
PMID: 35037601 - 18
Plasma neurofilament light chain as a biomarker for fatal familial insomnia.
Hermann P, Canaslan S, Villar-Piqué A, et al.
European journal of neurology 2022; (29(6)):1841-1846 doi:10.1111/ene.15302.
PMID: 35212083
This page is for informational purposes only and is not medical advice. Decisions about predictive genetic testing for a child should be made with a qualified clinician and genetic counselor who understand your family's PRNP variant and local privacy laws.